Myriad Genetics (MYGN) Stock
Genetic testing company for hereditary cancer screening. Here's the price, business snapshot, and what's worth knowing about Myriad Genetics in October 2026.
Myriad Genetics (MYGN) is a US-based molecular diagnostics company focused on hereditary cancer screening, oncology companion diagnostics and predictive tests that inform treatment decisions. It generates revenue from diagnostic testing services, licensing intellectual property and partnerships with biopharma for companion diagnostics. With a market capitalisation of about $749.94M, it sits in the small-cap segment and can show above-average volatility compared with larger peers. Investors should understand the company’s sensitivity to reimbursement policies, regulatory decisions and competitive pressure from other diagnostics firms. Clinical validation, new test launches or favourable payer coverage can act as catalysts, while declines in test volumes or adverse rulings can weigh on results. This summary is for educational purposes only and not personalised investment advice; suitability depends on individual circumstances and investors should consider risk tolerance, diversification and seek professional advice if needed.
Myriad Genetics (MYGN) Stock Forecast
Analyst price target, next 12 months
$12.49
+175.1% vs today's $4.54
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Myriad Genetics have a consensus 12-month target of $12.49, above the current price of $4.54.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 30 Jul 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts suggest holding Myriad Genetics stock, expecting a future price increase to $12.49.
Financial Health
Myriad Genetics is performing well with solid revenue and profit margins, indicating strong business operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Genetic Testing Focus
Specialises in hereditary cancer and oncology tests; rising demand for personalised medicine could support growth, though reimbursement and competition create uncertainty.
Growth & Catalysts
New test approvals, partnerships and improved payer coverage can boost revenue, but volumes and pricing remain variable and may cause swings in results.
Market & Risks
Market cap under $1bn implies small‑cap risks such as lower liquidity and earnings unpredictability; regulatory and reimbursement outcomes are key drivers.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
